In re Seroquel XR (Extended Release Quetiapine Fumarate) Litig., No. 20-cv-01076 (D. Del.)

In the Seroquel case, Faruqi & Faruqi represents a proposed class of direct purchasers of AstraZeneca’s Seroquel XR, a prescription drug treatment for schizophrenia, bipolar disorder, and depression.  The complaint alleges that AstraZeneca entered into reverse payment agreements with Handa Pharmaceuticals and Accord Pharmaceuticals that induced the two generic manufacturers to delay launching their generic versions of Seroquel XR.